Logo image of MRNS

MARINUS PHARMACEUTICALS INC (MRNS) Stock Fundamental Analysis

NASDAQ:MRNS - Nasdaq - US56854Q2003 - Common Stock - Currency: USD

0.55  +0 (+0.09%)

Premarket: 0.5491 0 (-0.16%)

Fundamental Rating

2

Overall MRNS gets a fundamental rating of 2 out of 10. We evaluated MRNS against 192 industry peers in the Pharmaceuticals industry. Both the profitability and financial health of MRNS have multiple concerns. MRNS is quite expensive at the moment. It does show a decent growth rate.


Dividend Valuation Growth Profitability Health

Quickly go to:

1

1. Profitability

1.1 Basic Checks

MRNS had negative earnings in the past year.
MRNS had a negative operating cash flow in the past year.
In the past 5 years MRNS always reported negative net income.
MRNS had a negative operating cash flow in each of the past 5 years.
MRNS Yearly Net Income VS EBIT VS OCF VS FCFMRNS Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 -50M -100M

1.2 Ratios

MRNS's Return On Assets of -220.81% is on the low side compared to the rest of the industry. MRNS is outperformed by 90.81% of its industry peers.
Industry RankSector Rank
ROA -220.81%
ROE N/A
ROIC N/A
ROA(3y)-54.19%
ROA(5y)-53.62%
ROE(3y)-348.39%
ROE(5y)-232.49%
ROIC(3y)N/A
ROIC(5y)N/A
MRNS Yearly ROA, ROE, ROICMRNS Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 -200 -400 -600 -800

1.3 Margins

With an excellent Gross Margin value of 90.17%, MRNS belongs to the best of the industry, outperforming 92.97% of the companies in the same industry.
The Profit Margin and Operating Margin are not available for MRNS so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 90.17%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
MRNS Yearly Profit, Operating, Gross MarginsMRNS Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 0 -1K -2K -3K -4K

More info and screens

1

2. Health

2.1 Basic Checks

MRNS does not have a ROIC to compare to the WACC, probably because it is not profitable.
The number of shares outstanding for MRNS has been increased compared to 1 year ago.
The number of shares outstanding for MRNS has been increased compared to 5 years ago.
MRNS has a worse debt/assets ratio than last year.
MRNS Yearly Shares OutstandingMRNS Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 10M 20M 30M 40M 50M
MRNS Yearly Total Debt VS Total AssetsMRNS Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 50M 100M 150M 200M 250M

2.2 Solvency

Based on the Altman-Z score of -20.05, we must say that MRNS is in the distress zone and has some risk of bankruptcy.
MRNS has a worse Altman-Z score (-20.05) than 87.03% of its industry peers.
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Altman-Z -20.05
ROIC/WACCN/A
WACC11.46%
MRNS Yearly LT Debt VS Equity VS FCFMRNS Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 0 50M -50M 100M -100M

2.3 Liquidity

A Current Ratio of 1.66 indicates that MRNS should not have too much problems paying its short term obligations.
Looking at the Current ratio, with a value of 1.66, MRNS is doing worse than 67.03% of the companies in the same industry.
MRNS has a Quick Ratio of 1.47. This is a normal value and indicates that MRNS is financially healthy and should not expect problems in meeting its short term obligations.
Looking at the Quick ratio, with a value of 1.47, MRNS is doing worse than 63.78% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 1.66
Quick Ratio 1.47
MRNS Yearly Current Assets VS Current LiabilitesMRNS Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 50M 100M 150M 200M 250M

More info and screens

6

3. Growth

3.1 Past

MRNS shows a small growth in Earnings Per Share. In the last year, the EPS has grown by 7.92%.
MRNS shows a small growth in Revenue. In the last year, the Revenue has grown by 1.63%.
MRNS shows a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 162.16% yearly.
EPS 1Y (TTM)7.92%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%31.15%
Revenue 1Y (TTM)1.63%
Revenue growth 3Y162.16%
Revenue growth 5YN/A
Sales Q2Q%16.39%

3.2 Future

The Earnings Per Share is expected to grow by 15.60% on average over the next years. This is quite good.
Based on estimates for the next years, MRNS will show a very strong growth in Revenue. The Revenue will grow by 31.95% on average per year.
EPS Next Y19.91%
EPS Next 2Y34.46%
EPS Next 3Y23.56%
EPS Next 5Y15.6%
Revenue Next Year9.81%
Revenue Next 2Y31.57%
Revenue Next 3Y24.44%
Revenue Next 5Y31.95%

3.3 Evolution

Although the future Revenue growth is still strong, it is not able to hold up the even more excellent growth rate of the past years.
MRNS Yearly Revenue VS EstimatesMRNS Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2016 2018 2020 2022 2024 2026 2028 2030 2032 20M 40M 60M 80M 100M
MRNS Yearly EPS VS EstimatesMRNS Yearly EPS VS EstimatesYearly EPS VS Estimates 2014 2016 2018 2020 2022 2024 2026 2028 2030 2032 0 -2 -4 -6 -8 -10

More info and screens

1

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for MRNS. In the last year negative earnings were reported.
Also next year MRNS is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
MRNS Price Earnings VS Forward Price EarningsMRNS Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 10 20 30

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
MRNS Per share dataMRNS EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 -1 -2

4.3 Compensation for Growth

MRNS's earnings are expected to grow with 23.56% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y34.46%
EPS Next 3Y23.56%

More info and screens

0

5. Dividend

5.1 Amount

MRNS does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

MARINUS PHARMACEUTICALS INC

NASDAQ:MRNS (2/10/2025, 8:13:23 PM)

Premarket: 0.5491 0 (-0.16%)

0.55

+0 (+0.09%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)11-12 2024-11-12/amc
Earnings (Next)03-11 2025-03-11/amc
Inst Owners63.59%
Inst Owner Change-28.84%
Ins Owners0.32%
Ins Owner Change-21.99%
Market Cap30.37M
Analysts73.85
Price Target1.09 (98.18%)
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)-0.15%
Min EPS beat(2)-0.53%
Max EPS beat(2)0.22%
EPS beat(4)1
Avg EPS beat(4)-4.39%
Min EPS beat(4)-16.47%
Max EPS beat(4)0.22%
EPS beat(8)4
Avg EPS beat(8)1.33%
EPS beat(12)6
Avg EPS beat(12)-24.79%
EPS beat(16)8
Avg EPS beat(16)-20.52%
Revenue beat(2)0
Avg Revenue beat(2)-13.95%
Min Revenue beat(2)-16.82%
Max Revenue beat(2)-11.09%
Revenue beat(4)0
Avg Revenue beat(4)-14.36%
Min Revenue beat(4)-17.5%
Max Revenue beat(4)-11.09%
Revenue beat(8)4
Avg Revenue beat(8)8.04%
Revenue beat(12)5
Avg Revenue beat(12)33.61%
Revenue beat(16)7
Avg Revenue beat(16)46.44%
PT rev (1m)-60.28%
PT rev (3m)-87.45%
EPS NQ rev (1m)-13.44%
EPS NQ rev (3m)37.61%
EPS NY rev (1m)-2.16%
EPS NY rev (3m)-6.38%
Revenue NQ rev (1m)1.09%
Revenue NQ rev (3m)-9.47%
Revenue NY rev (1m)0%
Revenue NY rev (3m)-4.78%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 0.97
P/FCF N/A
P/OCF N/A
P/B N/A
P/tB N/A
EV/EBITDA N/A
EPS(TTM)-2.44
EYN/A
EPS(NY)-0.5
Fwd EYN/A
FCF(TTM)-2.1
FCFYN/A
OCF(TTM)-2.08
OCFYN/A
SpS0.57
BVpS-1.21
TBVpS-1.21
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -220.81%
ROE N/A
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 90.17%
FCFM N/A
ROA(3y)-54.19%
ROA(5y)-53.62%
ROE(3y)-348.39%
ROE(5y)-232.49%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score2
Asset Turnover0.49
Health
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 224.53%
Cap/Sales 3.75%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 1.66
Quick Ratio 1.47
Altman-Z -20.05
F-Score2
WACC11.46%
ROIC/WACCN/A
Cap/Depr(3y)415.27%
Cap/Depr(5y)277.02%
Cap/Sales(3y)8.72%
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)7.92%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%31.15%
EPS Next Y19.91%
EPS Next 2Y34.46%
EPS Next 3Y23.56%
EPS Next 5Y15.6%
Revenue 1Y (TTM)1.63%
Revenue growth 3Y162.16%
Revenue growth 5YN/A
Sales Q2Q%16.39%
Revenue Next Year9.81%
Revenue Next 2Y31.57%
Revenue Next 3Y24.44%
Revenue Next 5Y31.95%
EBIT growth 1Y2.1%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y-0.7%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-1.8%
OCF growth 3YN/A
OCF growth 5YN/A